BTIG Reiterates Buy on Kazia Therapeutics, Maintains $34 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 86.3%

Neg 0% Neu 86.3% Pos 0%

BTIG analyst Kambiz Yazdi reiterates Kazia Therapeutics (NASDAQ:KZIA) with a Buy and maintains $34 price target.

Comments

No comments yet. Be the first!